

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)



(10) International Publication Number
WO 2022/008688 A1

(51) International Patent Classification:

C07K 16/30 (2006.01) A61K 51/04 (2006.01)
C07K 16/44 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2021/069072

(22) International Filing Date:

08 July 2021 (08.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2020/069561
10 July 2020 (10.07.2020) EP
21151246.2 12 January 2021 (12.01.2021) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; 150 Clove Road, Overlook at Great Notch, Suite 8, Little Falls, New Jersey 07424 (US).

(72) Inventors: **HAAS, Alexander**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **IMHOF-JUNG, Sabine**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FROST, Sofia**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS




FIG. 25

(57) Abstract: The present invention relates to a set of antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same. The antibodies each comprising a Fab binding to the target antigen fused at the C-terminus of the VH to the N-terminus of the Fc and a VH or VL binding to a radiolabelled compound. The VH or VL are fused at the C-terminus to the N-terminus of the Fc. VH and VL form an antigen binding site when the antibody binds via the scFv to the target antigen.

WO 2022/008688 A1